为解决先天性肾上腺皮质增生症(CAH)合并中枢性性早熟(CPP)患儿成年身高受损问题，天津医科大学总医院团队开展了一项联合治疗方案研究。通过GnRHa（促性腺激素释放激素类似物）、rhGH（重组人生长激素）与阿那曲唑（芳香化酶抑制剂）的三联疗法，显著改善 ...

Crinecerfont vs placebo was associated with lower glucocorticoid dose needs and improved hormone control among pediatric ...

Without enough cortisol, the child or person with classic CAH is going to be unable to make enough blood sugar, enough blood pressure in order to maintain normal life. Classic CAH is typically ...

which leads to many follow-up evaluations of children with positive first-tier screen results who do not have CAH. Positive predictive values might be improved by second-tier screening using LC ...

In both children and adults, the drug allows for decreasing glucocorticoid dosing to physiological levels while still ...

Crinecerfont gained FDA approval in December 2024 as a first-in-class treatment for CAH patients ages 4 and older based on ...

Congenital adrenal hyperplasia (CAH) includes a group of genetic (inherited) disorders that affect your adrenal glands. These ...

The defect that causes CAH is passed down from both parents to their child. According to the National Organization for Rare Diseases, CAH occurs in around one out of every 10,000-15,000 children.

Children with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency require treatment with glucocorticoids, usually at supraphysiologic doses, to address cortisol ...

In patients with classic congenital adrenal hyperplasia, crinecerfont conferred meaningful reductions in glucocorticoid dose ...

Sexual precocity and a testicular mass can result from a Leydig cell tumor or from simple virilizing CAH with adrenal rests in the testes. These diagnoses are usually distinguished by very high ...